Notes to the Condensed Consolidated Interim Financial Statements
of the Bayer Group as of June 30, 2016

Key Data by Segment

Key Data by Segment – Second Quarter 2016

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

Q2
2015

Q2
2016

 

Q2
2015

Q2
2016

 

Q2
2015

Q2
2016

 

Q2
2015

Q2
2016

 

 


million


million

 


million


million

 


million


million

 


million


million

2015 figures restated

1

For definition see Interim Group Management Report, “Overview of Sales, Earnings and Financial Position.”

2

For definition see Interim Group Management Report, “Calculation of EBIT(DA) Before Special Items.”

3

For definition see Interim Group Management Report, “Statement of Cash Flows.”

Net sales (external)

 

3,890

4,104

 

1,590

1,553

 

2,636

2,518

 

428

426

Change1

 

+17.0%

+5.5%

 

+70.6%

–2.3%

 

+10.3%

–4.5%

 

+19.6%

–0.5%

Currency-adjusted change1

 

+9.3%

+8.4%

 

+63.7%

+4.0%

 

+0.3%

+0.7%

 

+6.4%

+4.2%

Intersegment sales

 

8

8

 

1

3

 

8

8

 

6

1

Net sales (total)

 

3,898

4,112

 

1,591

1,556

 

2,644

2,526

 

434

427

EBIT2

 

772

988

 

191

190

 

561

512

 

105

93

EBIT before special items2

 

850

999

 

252

222

 

589

542

 

111

93

EBITDA before special items2

 

1,193

1,352

 

362

328

 

722

663

 

120

100

Gross cash flow3

 

807

871

 

241

237

 

529

468

 

83

69

Net cash flow3

 

491

310

 

161

241

 

752

1,088

 

85

48

Depreciation, amortization and impairments

 

347

354

 

110

107

 

133

121

 

8

7

Continuation of the previous table

 

 

Reconciliation

 

 

 

 

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Life Sciences

 

Covestro

 

Group

 

 

Q2 2015

Q2 2016

 

Q2 2015

Q2 2016

 

Q2 2015

Q2 2016

 

Q2 2015

Q2 2016

 

Q2 2015

Q2 2016

 

 


million


million

 


million


million

 


million


million

 


million


million

 


million


million

2015 figures restated

1

For definition see Interim Group Management Report “Overview of Sales, Earnings and Financial Position.”

2

For definition see Interim Group Management Report “Calculation of EBIT(DA) Before Special Items.”

3

For definition see Interim Group Management Report “Statement of Cash Flows.”

Net sales (external)

 

273

256

 

1

1

 

8,818

8,858

 

3,185

2,975

 

12,003

11,833

Change1

 

–0.7%

–6.2%

 

 

+21.1%

+0.5%

 

+11.2%

–6.6%

 

+18.3%

–1.4%

Currency-adjusted change1

 

+0.4%

–5.5%

 

 

+12.8%

+4.7%

 

+0.6%

–3.9%

 

+9.3%

+2.4%

Intersegment sales

 

593

478

 

(630)

(516)

 

 

14

18

 

Net sales (total)

 

866

734

 

(629)

(515)

 

 

3,199

2,993

 

12,003

11,833

EBIT2

 

24

18

 

(108)

(30)

 

1,545

1,771

 

278

367

 

1,823

2,138

EBIT before special items2

 

40

40

 

(101)

(21)

 

1,741

1,875

 

337

367

 

2,078

2,242

EBITDA before special items2

 

84

88

 

(99)

(20)

 

2,382

2,511

 

506

543

 

2,888

3,054

Gross cash flow3

 

219

321

 

(73)

(28)

 

1,806

1,938

 

359

428

 

2,165

2,366

Net cash flow3

 

85

170

 

26

(174)

 

1,600

1,683

 

360

309

 

1,960

1,992

Depreciation, amortization and impairments

 

44

48

 

2

1

 

644

638

 

170

176

 

814

814

Key Data by Segment – Half Year 2016

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

H1 2015

H1 2016

 

H1 2015

H1 2016

 

H1 2015

H1 2016

 

H1 2015

H1 2016

 

 


million


million

 


million


million

 


million


million

 


million


million

2015 figures restated

1

For definition see Interim Group Management Report, “Overview of Sales, Earnings and Financial Position.”

2

For definition see Interim Group Management Report, “Calculation of EBIT(DA) Before Special Items.”

3

For definition see Interim Group Management Report, “Statement of Cash Flows.”

4

Full-time equivalents

Net sales (external)

 

7,452

7,993

 

3,146

3,073

 

5,642

5,454

 

814

834

Change1

 

+15.7%

+7.3%

 

+69.6%

–2.3%

 

+8.2%

–3.3%

 

+18.3%

+2.5%

Currency-adjusted change1

 

+7.8%

+10.2%

 

+63.3%

+3.1%

 

+0.8%

+1.0%

 

+6.3%

+6.4%

Intersegment sales

 

18

15

 

2

4

 

18

17

 

7

2

Net sales (total)

 

7,470

8,008

 

3,148

3,077

 

5,660

5,471

 

821

836

EBIT2

 

1,519

1,686

 

365

433

 

1,416

1,467

 

170

207

EBIT before special items2

 

1,621

1,928

 

515

497

 

1,491

1,500

 

208

208

EBITDA before special items2

 

2,278

2,613

 

731

711

 

1,743

1,752

 

222

222

Gross cash flow3

 

1,561

1,832

 

468

522

 

1,220

1,234

 

155

155

Net cash flow3

 

1,303

1,044

 

446

438

 

(29)

422

 

205

28

Depreciation, amortization and impairments

 

661

917

 

216

228

 

257

252

 

35

14

Number of employees (as of June 30)4

 

41,140

40,197

 

13,700

13,085

 

23,592

22,839

 

3,818

3,859

Continuation of the previous table

 

 

Reconciliation

 

 

 

 

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Life Sciences

 

Covestro

 

Group

 

 

H1 2015

H1 2016

 

H1 2015

H1 2016

 

H1 2015

H1 2016

 

H1 2015

H1 2016

 

H1 2015

H1 2016

 

 


million


million

 


million


million

 


million


million

 


million


million

 


million


million

2015 figures restated

1

For definition see Interim Group Management Report, “Overview of Sales, Earnings and Financial Position.”

2

For definition see Interim Group Management Report, “Calculation of EBIT(DA) Before Special Items.”

3

For definition see Interim Group Management Report, “Statement of Cash Flows.”

4

Full-time equivalents

Net sales (external)

 

541

506

 

2

2

 

17,597

17,862

 

6,199

5,825

 

23,796

23,687

Change1

 

–2.3%

–6.5%

 

 

+19.3%

+1.5%

 

+9.4%

–6.0%

 

+16.5%

–0.5%

Currency-adjusted change1

 

–2.3%

–5.9%

 

 

+11.8%

+5.3%

 

–0.7%

–4.3%

 

+8.4%

+2.8%

Intersegment sales

 

1,130

903

 

(1,202)

(980)

 

 

27

39

 

Net sales (total)

 

1,671

1,409

 

(1,200)

(978)

 

 

6,226

5,864

 

23,796

23,687

EBIT2

 

43

21

 

(262)

(59)

 

3,251

3,755

 

497

703

 

3,748

4,458

EBIT before special items2

 

65

46

 

(251)

(48)

 

3,649

4,131

 

598

703

 

4,247

4,834

EBITDA before special items2

 

154

141

 

(248)

(45)

 

4,880

5,394

 

930

1,047

 

5,810

6,441

Gross cash flow3

 

268

400

 

(181)

(48)

 

3,491

4,095

 

671

835

 

4,162

4,930

Net cash flow3

 

57

167

 

174

(33)

 

2,156

2,066

 

523

478

 

2,679

2,544

Depreciation, amortization and impairments

 

89

95

 

3

3

 

1,261

1,509

 

354

344

 

1,615

1,853

Number of employees (as of June 30)4

 

19,482

19,114

 

731

752

 

102,463

99,846

 

15,071

15,730

 

117,534

115,576